http://www.ft.com/companies/pharmaceuticals The latest drugs, health care and pharmaceutical news from the Financial Times, with expert company and industry analysis on FT.com en (PICS-1.1 "http://www.classify.org/safesurf/" L gen true for "http://www.ft.com/" r (SS~~000 1)) © Copyright The Financial Times Ltd 2013. "FT" and "Financial Times" are trademarks of the Financial Times. See http://www.ft.com/servicestools/help/terms#legal1 for the terms and conditions of reuse. Tue, 21 May 2013 22:44:41 GMT Wed, 22 May 2013 07:32:44 GMT client.support@ft.com (Client Support) 15 Newspapers http://www.ft.com/rss/companies/pharmaceuticals http://im.ft-static.com/m/img/rss/RSS_Default_Image.png http://www.ft.com/companies/pharmaceuticals http://www.ft.com/cms/s/0/4670a160-c232-11e2-ab66-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct Doctors specialising in diseases of the central nervous system and mental disorders receive more money from drug companies than their counterparts Tue, 21 May 2013 22:44:41 GMT http://www.ft.com/cms/s/0/4670a160-c232-11e2-ab66-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct 4670a160-c232-11e2-ab66-00144feab7de http://www.ft.com/cms/s/0/2fbd5a72-c222-11e2-ab66-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct Criticism comes at a time when there is growing scrutiny over the use of the drug and questions about the quality of information on the product Tue, 21 May 2013 16:23:22 GMT http://www.ft.com/cms/s/0/2fbd5a72-c222-11e2-ab66-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct 2fbd5a72-c222-11e2-ab66-00144feab7de http://www.ft.com/cms/s/3/a1678cf6-c173-11e2-b93b-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct Acquisitive companies are opaque – there is tricky accounting involved and growth rates are hard to estimate. The new Actavis will be difficult to assess Mon, 20 May 2013 18:03:25 GMT http://www.ft.com/cms/s/3/a1678cf6-c173-11e2-b93b-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct a1678cf6-c173-11e2-b93b-00144feab7de http://www.ft.com/cms/s/0/41e8e9c2-c124-11e2-b93b-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct Irish pharmaceutical group announces fresh debt and acquisition plans as Royalty steps up pressure on Elan with an improved $12.50-a-share cash offer Mon, 20 May 2013 17:01:52 GMT http://www.ft.com/cms/s/0/41e8e9c2-c124-11e2-b93b-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct 41e8e9c2-c124-11e2-b93b-00144feab7de http://www.ft.com/cms/s/0/4d5df734-c147-11e2-9767-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct All-stock deal could bring an end to recent merger talks around Actavis and will create a speciality pharma group with an annual $11bn in sales Mon, 20 May 2013 15:53:21 GMT http://www.ft.com/cms/s/0/4d5df734-c147-11e2-9767-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct 4d5df734-c147-11e2-9767-00144feab7de http://www.ft.com/cms/s/0/509dd604-c0a1-11e2-aa8e-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct The potential costs of global tax disputes by FTSE 100 companies fell by more than a third, suggesting a waning appetite for conflict Sun, 19 May 2013 23:03:41 GMT http://www.ft.com/cms/s/0/509dd604-c0a1-11e2-aa8e-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct 509dd604-c0a1-11e2-aa8e-00144feab7de http://www.ft.com/cms/s/0/b1501ffa-bd6f-11e2-a735-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct Some awkward questions arise with new medical technology. Pre-emptive mastectomy is a procedure in which certain familiar distinctions break down Fri, 17 May 2013 18:18:02 GMT http://www.ft.com/cms/s/0/b1501ffa-bd6f-11e2-a735-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct b1501ffa-bd6f-11e2-a735-00144feab7de http://www.ft.com/cms/s/0/99b617dc-be19-11e2-9b27-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct Round-up of boardroom trading Fri, 17 May 2013 17:38:52 GMT http://www.ft.com/cms/s/0/99b617dc-be19-11e2-9b27-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct 99b617dc-be19-11e2-9b27-00144feab7de http://www.ft.com/cms/s/0/0bb62e5c-be39-11e2-bb35-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct Irish pharmaceutical group has turned down an offer from a US private equity group saying it was ‘grossly inadequate’ and a ‘misplaced or naive offer’ Thu, 16 May 2013 16:02:50 GMT http://www.ft.com/cms/s/0/0bb62e5c-be39-11e2-bb35-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct 0bb62e5c-be39-11e2-bb35-00144feab7de http://www.ft.com/cms/s/0/642f1406-bd79-11e2-a735-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct Prof Sir Michael Rawlins’ move comes at a time of growing debate over the ‘revolving door’ between senior public and private sector posts Wed, 15 May 2013 22:38:00 GMT http://www.ft.com/cms/s/0/642f1406-bd79-11e2-a735-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct 642f1406-bd79-11e2-a735-00144feab7de http://www.ft.com/cms/s/0/6c3ebaa2-bd6a-11e2-a735-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct In a pioneering study, researchers found malaria modifies mosquitoes’ sense of smell to make them nearly four times more attracted to humans Wed, 15 May 2013 21:05:39 GMT http://www.ft.com/cms/s/0/6c3ebaa2-bd6a-11e2-a735-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct 6c3ebaa2-bd6a-11e2-a735-00144feab7de http://www.ft.com/cms/s/0/36c22356-b422-11e2-ace9-00144feabdc0.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct Pharmaceutical companies fear that the battle raging in India over generic medicines will inspire emerging economies to change their patent laws Wed, 15 May 2013 19:12:36 GMT http://www.ft.com/cms/s/0/36c22356-b422-11e2-ace9-00144feabdc0.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct 36c22356-b422-11e2-ace9-00144feabdc0 http://www.ft.com/cms/s/0/0af92ace-bcb2-11e2-9519-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct Human “therapeutic cloning” back on the scientific agenda as US-based team for the first time produce embryonic stem cells from those of adults Wed, 15 May 2013 16:33:01 GMT http://www.ft.com/cms/s/0/0af92ace-bcb2-11e2-9519-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct 0af92ace-bcb2-11e2-9519-00144feab7de http://www.ft.com/cms/s/0/23eab2c0-bca6-11e2-9519-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct R&D enterprise seeks novel treatments for cancer and disorders of the nervous system and hopes to secure a licensing deal for ETS2101 by 2017 Tue, 14 May 2013 17:13:22 GMT http://www.ft.com/cms/s/0/23eab2c0-bca6-11e2-9519-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct 23eab2c0-bca6-11e2-9519-00144feab7de http://www.ft.com/cms/s/0/95cd7e60-bbd7-11e2-a4b4-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct The scale of the rally suggests caution is warranted; after all, nothing much has changed this year, aside from investor sentiment Mon, 13 May 2013 21:04:58 GMT http://www.ft.com/cms/s/0/95cd7e60-bbd7-11e2-a4b4-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct 95cd7e60-bbd7-11e2-a4b4-00144feab7de http://www.ft.com/cms/s/0/caaf8714-bb9f-11e2-82df-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct Irish drugs group seeks to weaken Royalty Pharma’s hostile bid in a fresh example of the increasingly diverse range of partnerships in pharmaceuticals Mon, 13 May 2013 15:43:54 GMT http://www.ft.com/cms/s/0/caaf8714-bb9f-11e2-82df-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct caaf8714-bb9f-11e2-82df-00144feab7de http://www.ft.com/cms/s/3/3b205c52-bbd8-11e2-a4b4-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct In its attempt to escape the clutches of Royalty Pharma, the Dublin-based drugs company is turning itself into a bigger version of its stalker Mon, 13 May 2013 15:04:07 GMT http://www.ft.com/cms/s/3/3b205c52-bbd8-11e2-a4b4-00144feab7de.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct 3b205c52-bbd8-11e2-a4b4-00144feab7de http://www.ft.com/cms/s/0/4b492f40-b9a9-11e2-9a9f-00144feabdc0.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct Generic drugmaker’s early talks with pharmaceuticals company sent its share price soaring by 20 per cent, adding $800m to its market value Fri, 10 May 2013 22:15:19 GMT http://www.ft.com/cms/s/0/4b492f40-b9a9-11e2-9a9f-00144feabdc0.html?ftcamp=published_links%2Frss%2Fcompanies_pharmaceuticals%2Ffeed%2F%2Fproduct 4b492f40-b9a9-11e2-9a9f-00144feabdc0